Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Actinium Pharmaceuticals, Inc. (ATNM) had Return on Tangible Equity of -116.74% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-38.24M |
|
-- |
|
-- |
|
$42.12M |
|
$-42.12M |
|
$3.88M |
|
$-38.24M |
|
$-38.24M |
|
$-38.24M |
|
$-38.24M |
|
$-38.24M |
|
$-38.24M |
|
$-42.12M |
|
$-41.31M |
|
30.07M |
|
30.07M |
|
$-1.27 |
|
$-1.27 |
|
| Balance Sheet Financials | |
$74.51M |
|
$0.36M |
|
$2.39M |
|
$76.90M |
|
$8.15M |
|
$0.01M |
|
$35.99M |
|
$44.14M |
|
$32.76M |
|
$32.76M |
|
$32.76M |
|
31.20M |
|
| Cash Flow Statement Financials | |
$-33.07M |
|
$-0.01M |
|
$29.32M |
|
$76.99M |
|
$73.23M |
|
$-3.76M |
|
$5.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.14 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-33.08M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-116.74% |
|
|
Return on Tangible Equity |
-116.74% |
-49.73% |
|
-116.71% |
|
$1.05 |
|
$-1.10 |
|
$-1.10 |
|